Complications, co-morbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany - results from the CODE-2^TM study

Summary

In this study, prevalence and incidence of complications as well as co-morbidity in type 2 diabetes patients in Germany were evaluated as part of a cost-of-illness study (CODE-2^TM, Costs of Diabetes in Europe - Type 2)

In a pre-study, 197 general practitioners and diabetes specialists all over Germany provided data on the complication status of 2701 randomly selected patients with type 2 diabetes. The patients were grouped into five mutually exclusive strata. This pre-study was performed to generate a general overview on complication status to select proper patients for the main study.

The main study was performed on stratified samples derived from the pre-study. Irrespective of the real prevalence of the five strata, an equal number of 160 were randomly selected from each stratum. Thus, rare complications were also covered in the study. Data from 809 patients were collected retrospectively on the basis of medical files during interviews with the physician. To achieve representative estimates of absolute prevalence and incidence of diabetes-related complications in Germany, results were weighted using frequencies of the strata.

Severe complications were diagnosed in 50% of these patients. Prevalences were: 10.56% myocardial infarction, 6.66% stroke, 3.97% foot ulcer, 2.30% amputations and 1.34% blindness. Overall incidences in the diabetes population were estimated at 0.78% myocardial infarction, 1.28% stroke and 0.80% amputations. 23% of the diabetes patients suffered from 2 or more complications. The complication status became considerably worse with increasing time since the diagnosis of diabetes. The mean HbA_1c level was 7.51% (i.e. 122% of the upper limit of the respective normal ranges).

The presence of complications and co-morbidity in type 2 diabetes patients was a frequent finding. This underlines the importance of complications in diabetes patients and the necessity to increase any means of prevention in order to relieve the personal and economic burden of type 2 diabetes.

Diabetes mellitus - Complications - Blood glucose - Prevalence - Incidence

References

• 1 Brown J B, Pedula K L, Bakst A W. The progressive cost of complications in type 2 diabetes mellitus.  Arch Intern Med. 1999;  159 1873-1880
• 2 Delcourt C, Vauzelle-Kervroedan F, Cathelineau G, Papoz L. Codiab-Inserm-Zeneca Pharma Study Group . Low prevalence of long-term complications in non-insulin-dependent diabetes mellitus in France: a multicenter study.  1998;  J Diab Comp. 1998;  12 88-95
• 3 Federal Statistical Office (Ed.) .Health report for Germany. Metzler-Poeschel, Stuttgart 1998: 237-463
• 4 Frei U, Schober-Halstenberg H J. Nierenersatztherapie in Deutschland: Bericht über Dialysebehandlung und Nierentransplantation in Deutschland 1997/1998. QuaSi-Niere gGmbH. ISBN 3-00-005973-3. Available from URL: http://www.quasi-niere.de June 2000
• 5 Gloeser S. Gesundheits-Paß Diabetes: Versorgungsqualität soll verbessert werden.  Deutsches Ärzteblatt. 1996;  8 A-438
• 6 Hasche H. Was kosten Typ II Diabetiker?.  Fortschr Med. 1997;  115 43-44
• 7 Hasche H, Flink K, Herbold M, Lempcke H L, Ley H G, Schwinn G, Spork G, Janka H U. Multizentrische Studie zur Effektivität der diabetologischen Schwerpunktpraxis.  Deutsches Ärzteblatt. 1997;  94 B-2429-2434
• 8 Janka H U. Prävalenz des Diabetes mellitus und der Folgekrankheiten.  Diabetologie Informationen. 1996;  4 243-253
• 9 Junghänel J, Müller U A, Koehler S, Koehler C, Schumann A. Quality of diabetes care in a general practice network.  ExpClin Endocrinol Diabetes. 108 ((Suppl 1)) 2000;  163
• 10 Leese B. The costs of diabetes and its complications.  Soc Sci Med. 1992;  35 1303-1310
• 11 Liebl A, Goertz A, Henkel B, Spannheimer A. Kostet der Zucker 20 Milliarden pro Jahr?.  MMW-Fortschr Med. 2000;  142 39-42
• 12 Lippert J, Ritz E, Schwarzbeck A, Schneider P. The rising tide of endstage renal failure from diabetic nephropathy type II - an epidemiological analysis.  Nephrol Dial Transplant. 1995;  10 462-467
• 13 Michaelis D, Jutzi E. Epidemiologie des Diabetes mellitus in der Bevölkerung der ehemaligen DDR: Alters- und geschlechtsspezifische Inzidenz- und Prävalenztrends im Zeitraum 1960-1987.  Z Klin Med. 1991;  46 59-64
• 14 Palitzsch K D, Nusser J, Arndt H, Enger I, Zietz B, Hügl S, Cuk A, Schäffler A, Büttner R, Frick E, Rath H, Schölmerich J. Diabetomobil-Studiengruppe . Die Prävalenz des Diabetes mellitus wird in Deutschland deutlich unterschätzt - eine bundesweite epidemiologische Studie auf der Basis einer HbA_1c-Analyse.  Diab Stoffw. 1999;  8 189-200
• 15 Rathmann W, Haastert B, Roseman J, Gries F A, Giani G. Prescription drug use and costs among diabetic patients in primary health care practices in Germany.  Diabetes Care. 1998;  21 389-397
• 16 Standl E, Stiegler H. Mangelnder Erfolg bei der Reduktion von Amputationen bei Diabetikern in Deutschland. In: Berger M, Trautner C (eds) Die Forderungen von St. Vincent - Stand 1996 in Deutschland Kirchheim-Verlag, Mainz 1996: 73-79
• 17 Stein G, Sperrschneider H, Schneider S. Diabetic patients on renal replacement therapy.  Nephrol Dial Transplant. 1996;  11 1669
• 18 Thorvaldsen P, Kuulasmaa K, Rajakangas A M, Rastenyte D, Sarti C, Wilhelmsen L. Stroke trends in the WHO MONICA project.  Stroke. 1997;  28 500-506
• 19 Trautner C, Wagner W, Berger M. Untersuchungen zur Epidemiologie diabetesbedingter Erblindung in Deutschland.  Diab Stoffw. 1993;  2 203
• 20 Trautner C, Haastert B, Giani G, Berger M. Incidence of lower limb amputations and diabetes.  Diabetes Care. 1996;  19 1006-1009
• 21 Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality. 10-year results from 37 WHO-MONICA project populations. Monitoring trends and determinants in cardiovascular disease.  Lancet. 1999;  353 1547-1557
• 22 UK Prospective Diabetes Study (UKPDS) Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).  Lancet. 1998;  352 837-853
• 23 UK Prospective Diabetes Study (UKPDS) Group . Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).  Lancet. 1998;  352 854-865
• 24 Ziegler D, Gries F A, Spüler M, Lessmann F. The epidemiology of diabetic neuropathy.  J Diab Comp. 1992;  6 49-57